Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Trial Profile

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Hereditary autoinflammatory diseases
  • Focus Registrational; Therapeutic Use
  • Acronyms CLUSTER; Umbrella
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 04 Sep 2017 This trial has been completed in Netherlands.
    • 10 Aug 2017 This trial has been completed in Ireland (end date: 04-07-2017 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top